Cargando…

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen

PURPOSE: The relationship between body mass index (BMI) and prostate cancer remains unclear. However, there is an inverse association between BMI and prostate-specific antigen (PSA), used for prostate cancer screening. We conducted this review to estimate the associations between BMI and (1) prostat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harrison, Sean, Tilling, Kate, Turner, Emma L., Martin, Richard M., Lennon, Rosie, Lane, J. Athene, Donovan, Jenny L., Hamdy, Freddie C., Neal, David E., Bosch, J. L. H. Ruud, Jones, Hayley E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105428/ https://www.ncbi.nlm.nih.gov/pubmed/32162172 http://dx.doi.org/10.1007/s10552-020-01291-3

Ejemplares similares

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
por: Gilbert, Rebecca, et al.
Publicado: (2018)

Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful?
por: Harrison, Sean, et al.
Publicado: (2016)

Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial
por: Walsh, Eleanor I., et al.
Publicado: (2016)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
por: Rosario, Derek J, et al.
Publicado: (2012)

Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy
por: Gilbert, Rebecca, et al.
Publicado: (2015)

Men’s knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study
por: Horwood, Jeremy P, et al.
Publicado: (2014)

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
por: Young, Grace J, et al.
Publicado: (2017)

The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals
por: Avery, Kerry NL, et al.
Publicado: (2014)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
por: Wade, Julia, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial
por: Keeney, Edna, et al.
Publicado: (2022)

Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: Opportunities for lifestyle modification
por: Hackshaw-McGeagh, Lucy E, et al.
Publicado: (2015)

Associations between an Obesity Related Genetic Variant (FTO rs9939609) and Prostate Cancer Risk
por: Lewis, Sarah J., et al.
Publicado: (2010)

Alcohol consumption and PSA-detected prostate cancer risk—A case-control nested in the ProtecT study
por: Zuccolo, Luisa, et al.
Publicado: (2013)

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)
por: Lane, Janet Athene, et al.
Publicado: (2022)

A model of the natural history of screen-detected prostate cancer
por: Metcalfe, C, et al.
Publicado: (2006)

Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP)
por: Merriel, Samuel William David, et al.
Publicado: (2017)

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial
por: Donovan, Jenny L., et al.
Publicado: (2018)

Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial
por: Wade, Julia, et al.
Publicado: (2015)

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial
por: Er, Vanessa, et al.
Publicado: (2017)

Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
por: Thorn, Joanna C., et al.
Publicado: (2023)

Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study
por: Metcalfe, C, et al.
Publicado: (2009)

Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case–control study
por: Gilbert, Rebecca, et al.
Publicado: (2014)

Evaluating best practice in informed consent discussions: a new method of evaluating information provision and patient understanding during trial recruitment consultations
por: Wade, Julia, et al.
Publicado: (2013)

Novel biomarkers for the detection of prostate cancer
por: Jakobsen, Niels Asger, et al.
Publicado: (2016)

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis
por: Pashayan, Nora, et al.
Publicado: (2015)

Exploring treatment preferences facilitated recruitment to randomized controlled trials
por: Mills, Nicola, et al.
Publicado: (2011)

Addressing patient treatment preferences at trial recruitment
por: Mills, Nicola, et al.
Publicado: (2011)

Evaluation of source data verification in a multicentre cancer trial (PROTECT)
por: Lane, J Athene, et al.
Publicado: (2013)

Understanding factors influencing questionnaire response rates to maximise retention in a long term complex intervention trial
por: Lane, Athene J, et al.
Publicado: (2011)

The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer
por: Noble, Sian M., et al.
Publicado: (2020)

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial
por: Johnston, Thomas J., et al.
Publicado: (2017)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
por: Dimitropoulou, P, et al.
Publicado: (2011)

Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis
por: Burton, Anya J., et al.
Publicado: (2021)

Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result
por: Macefield, R C, et al.
Publicado: (2010)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group
por: Roobol, Monique J., et al.
Publicado: (2011)

Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
por: Thorn, Joanna C, et al.
Publicado: (2016)

Updates of prostate cancer staging: Prostate-specific membrane antigen
por: Sathianathen, Niranjan J, et al.
Publicado: (2016)

Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)
por: Williams, Naomi J, et al.
Publicado: (2015)

Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer
por: Nyame, Yaw A, et al.
Publicado: (2020)

Pathogenesis of prostate cancer and hormone refractory prostate cancer
por: Girling, J. S., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_of8g9r96s46107ml0ho1j01o6a